Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04353388 · ClinicalTrials.gov registry record
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University
A clinical trial, sponsored by Beckman Coulter.
- Completed
- Registry status
- 1,139
- Enrollment target
NCT04353388: Completed study, sponsored by Beckman Coulter.
NCT04353388 is a clinical trial that has completed, run by Beckman Coulter. The registered enrollment target is 1,139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04353388 has completed, sponsored by Beckman Coulter.
- COMPLETED
- Registry status
- 1,139 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).
Primary Outcome
Validate MDW's ability to reduce time to first antibiotics ordered by physician (decision to treat)-Simulated
Interventions
- DIAGNOSTIC_TEST CBC-DIFF Monocyte Volume Width Distribution (MDW)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,139 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2020-07-17 |
What the finished NCT04353388 record still lists
NCT04353388 is an observational study that tracks outcomes without assigning an intervention. Its 1,139 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which CBC-DIFF Monocyte Volume Width Distribution (MDW) is the first listed.
NCT04353388 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04353388 about?
NCT04353388 is a clinical study titled "Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University". The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentatio...
What is the current status of trial NCT04353388?
This trial is currently completed. The enrollment target is 1,139 participants. The study started on 2020-02-03. Estimated completion is 2020-07-17.
What interventions are being tested in trial NCT04353388?
The interventions under investigation include: CBC-DIFF Monocyte Volume Width Distribution (MDW) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04353388?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06129864 · 1,145 participants · Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
- NCT06676319 · 1,147 participants · Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI